• KOL
    • Copd Patients
    • Dave Singh
    • Dave Singh: Influence Statistics

      Dave Singh

      Dave Singh

      Show email address

      University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. | Medicines Evaluation Unit, University of Manchester, Manchester University National ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Dave Singh:Expert Impact

      Concepts for whichDave Singhhas direct influence:Copd patients,Pulmonary disease,Obstructive pulmonary,Mild asthma,Hospitalised patients,Chronic obstructive,Severe asthma,Persistent asthma.

      Dave Singh:KOL impact

      Concepts related to the work of other authors for whichfor which Dave Singh has influence:Small airways,Severe asthma,Chronic obstructive,Pulmonary disease,Lung function,Copd patients,Sarscov2 infection.

      KOL Resume for Dave Singh

      Year
      2022

      University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.

      Medicines Evaluation Unit and.

      2021

      Medicines Evaluation Unit, University of Manchester, Manchester, UK

      From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) - both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.).

      2019

      Centre for Respiratory Medicine and Allergy, The University of Manchester, Manchester, UK

      2017

      University of Manchester, Medicines Evaluation Unit and University Hospital of South Manchester Foundation Trust, Manchester, United Kingdom

      2016

      Centre for Respiratory Medicine and Allergy, The University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK

      2015

      The University of Manchester, Centre for Respiratory and Allergy, Manchester Academic Health and Science Centre, University Hospital of South Manchester Foundation Trust, Manchester, UK.

      2012

      For author affiliations, see the Acknowledgements section

      2009

      U.S. Army RDECOM-ARDEC Advanced Energy Armament Systems Center, Bldg. 65N, Picatinny Arsenal, New Jersey, 07806, USA

      2008

      Medicines Evaluation Unit, The Langley Building, University Hospital of South Manchester NHS Trust, University of Manchester, Southmoor Road, Manchester M23 9QZ, UK.

      2006

      North West Lung Research Centre, South Manchester University Hospitals Trust Manchester, UK M23 9LT

      2000

      Center for Perinatal Biology, Loma Linda University Medical Center, Loma Linda, California 92350

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Dave Singh is among the top experts in the world.
      Concept World rank
      fine triple #6
      inhaled syk #6
      terms laboratory testing #13
      standardisation qct indices #13
      airway diseasedominant #13
      standardised qct #13
      qct indices emphysema #13
      standardisation qct #13
      qct indices #15
      inhaled nebulised ufh #16
      scanner conformity #18
      nebulised interferon #22
      trimaran trigger #23
      lower gas transfer #25
      inhaled nebulised #25
      airway wall geometry #26
      extrafine triple therapy #26
      nebulised unfractionated #26
      dna streptococcus tomography #27
      specific microbiome structures #27
      community composition lungs #27
      nebulised ufh #28
      patients severe subtypes #29
      disease delineate #29
      brushings copd #34
      count biopred #34
      copd eva #34
      ubiopred copd #34
      eva asthma #34
      bronchial brushings copd #34
      noneosinophilic copd cases #34
      airway disease copd #35
      suffering defined #35
      disease eva #36
      emphysemadominant #36
      young patients copd #37
      copd young patients #37
      prevotella pulmonary #42
      lung define #42
      young patients time #43
      copd biology #44
      transcriptome relationships #44
      streptococcus severe #46
      eosinophilic versus #48
      eosinophilic asthma copd #48
      meta trial #49
      dominant copd #49
      indices emphysema #49
      plethysmography impulse #50
      designated mild #50
      Sign-in to see all concepts, it's free!

      Prominent publications by Dave Singh

      KOL-Index: 17552

      BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma.

      METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with ...

      Known for Small Airways Dysfunction | Asthma Control | Impulse Oscillometry | Prospective Cohort Study | Physiological Tests
      KOL-Index: 8930

      BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19.

      METHODS: We did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites. Adults aged 18 years or older and admitted to hospital ...

      Known for Patients Placebo | Nebulised Interferon | Sarscov2 Infection | Odds Ratio 95 | Covid19 Symptoms
      KOL-Index: 8782

      BACKGROUND: Whether the clinical or pathophysiologic significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma.

      METHODS: Subjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of ...

      Known for Blood Eosinophil | Asthma Copd | Gene Expression | Airway Disease | Lung Function
      KOL-Index: 8478

      EvA (Emphysema versus Airway disease) is a multicentre project to study mechanisms and identify biomarkers of emphysema and airway disease in chronic obstructive pulmonary disease (COPD). The objective of this study was to delineate objectively imaging-based emphysema-dominant and airway disease-dominant phenotypes using quantitative computed tomography (QCT) indices, standardised with a novel phantom-based approach.441 subjects with COPD (Global Initiative for Chronic Obstructive Lung ...

      Known for Computed Tomography | Airway Disease | Copd Phenotypes | Pulmonary Emphysema | Chronic Obstructive
      KOL-Index: 5545

      BACKGROUND: Changes in microbial community composition in the lung of patients suffering from moderate to severe COPD have been well documented. However, knowledge about specific microbiome structures in the human lung associated with CT defined abnormalities is limited.

      METHODS: Bacterial community composition derived from brush samples from lungs of 16 patients suffering from different CT defined subtypes of COPD and 9 healthy subjects was analyzed using a cultivation independent ...

      Known for Pulmonary Disease | Chronic Obstructive | Lung Microbiome | Bacterial Communities | Copd Patients
      KOL-Index: 4762

      The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes ...

      Known for Airway Disease | Eva Study | Computed Tomography | Pulmonary Emphysema | Blood Samples
      KOL-Index: 4377

      BACKGROUND: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.

      METHODS: We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 monoclonal antibody, in adults with severe ...

      Known for Severe Asthma | Controlled Trial | Airway Inflammation | 2 Type | Agents Antibodies
      KOL-Index: 3672

      AIMS: Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID-19. UFH has antiviral effects and prevents the SARS-CoV-2 virus' entry into mammalian cells. In addition, UFH has significant anti-inflammatory and anticoagulant properties, which limit progression of lung injury and vascular pulmonary thrombosis.

      METHODS: The INHALEd nebulised unfractionated HEParin ...

      Known for Unfractionated Heparin | Hospitalised Patients | Randomised Studies | Mechanical Ventilation | Anticoagulant Properties
      KOL-Index: 2624

      Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: "young" individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at ...

      Known for Chronic Obstructive | Pulmonary Disease | Respiratory Symptoms | Environment Interactions | Copd Older
      KOL-Index: 1649
      Known for Chronic Obstructive | Pulmonary Disease | Bacterial Infection
      KOL-Index: 1468

      The present study tested the hypothesis that acute treatment with 2, 3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) impairs fertility, disrupts the nocturnal melatonin rhythm, and suppresses lymphocyte function. Adult Siberian hamsters administered 2 or 100 microg TCDD/kg body weight/0.2 ml sesame oil had a delayed latency to first litter and an increased adult mortality compared to hamsters given 0.1 microg/kg or vehicle. Within 75 days of TCDD treatment, full reproductive capabilities were ...

      Known for Circadian Rhythm | Dioxin Tcdd | 2378 Tetrachlorodibenzo | Time Day
      KOL-Index: 863

      INTRODUCTION: Discordance between real-world prescribing patterns and global treatment guidelines for the treatment of chronic obstructive pulmonary disease (COPD) with inhaled single or dual long-acting bronchodilator maintenance therapy is increasingly being reported in the literature, particularly with regard to addition of inhaled corticosteroids (ICS). Patient-related factors, e.g. inhalation technique and inspiratory flow, are key to disease control in COPD. Treatment discordance ...

      Known for Pulmonary Disease | Chronic Obstructive

      Key People For Copd Patients

      Top KOLs in the world
      #1
      Bartolome R Celli†
      copd patients chronic obstructive pulmonary disease
      #2
      Peter M A Calverley
      chronic obstructive pulmonary disease patients copd
      #3
      Peter John Barnes
      nitric oxide chronic obstructive oxidative stress
      #4
      Jørgen Vestbo
      chronic obstructive pulmonary disease lung function
      #5
      Alvar G N Agustı́
      chronic obstructive pulmonary disease patients copd
      #6
      Paul Wyatt Jones
      chronic asthma pulmonary disease patients copd

      University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. | Medicines Evaluation Unit, University of Manchester, Manchester University National Health Service Foundation Trust, Manchester, UK | Medicines Evaluation Unit an

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.